A biologics license application was submitted to the FDA seeking the accelerated approval of RP1 (vusolimogene oderparepvec) plus nivolumab (Opdivo) for the treatment of adult patients with advanced melanoma who have received prior treatment with a regimen containing a PD1 inhibitor. The combination also received breakthrough therapy designation from the FDA for the same designation.
Melanoma News
Neoadjuvant Therapy NCCN Recommendations Take the Melanoma Field in a New Direction
Douglas B. Johnson, MD, MSCI, unpacks NCCN guideline updates in melanoma, detailing how neoadjuvant and TIL therapies have been notable advancements.
Scientists identify key mechanism in development of skin cancer
LMU researchers have discovered how the interplay between a key protein and an endolysosomal ion channel promotes tumor development in skin cancer.
New Study May Help Refine Sentinel Node Biopsy Decisions for Melanoma Patients
A new study presented at the Society for Melanoma Research annual meeting could influence how early-stage melanoma patients are selected for sentinel node biopsy, a surgical procedure often used to determine if melanoma has spread to the lymph nodes.